Aseptic Vial Cap prevents lyophilized drug contamination.
Share:
Press Release Summary:
Useful in pharmaceutical laboratories, .5 or .8 in. plastic Lyoseal cap seals vial and its standard stopper in one step inside lyophilizer's sterile environment eliminates risk of microbiological contamination. Product enables sealing of all medicine vials in lyophilizer itself in (class A) aseptic area, eliminating crimping and re-handling operations. Stopper top remains sterile when end-user removes flip-off cap, and cap cannot be put back on once it has been removed.
Original Press Release:
Lyoseal Aseptic Vial Cap Eliminates Risk of Contamination of Lyophilized Drugs
Chicago, October 30, 2006
BIOCORP has developed the Lyoseal cap, an innovative solution for sealing vials for lyophilized drugs. This patented device for use in pharmaceutical laboratories has been designed to seal a vial and its standard stopper in one step inside a lyophilizer in a sterile environment to help eliminate the risk of microbiological contamination.
The European Medicines Agency (EMEA) and the FDA recommend that "...partially stoppered freeze dried vials should be maintained in a sterile environment until the cap has been crimped." Lyoseal goes further by making it possible to seal all medicine vials in the lyophilizer itself, in a (class A) aseptic area. This eliminates the crimping operation required with a conventional aluminum seal (capping), and the re-handling that increase the risk of microbiological contamination of the medicines.
The top of the stopper remains sterile when the end-user removes the flip-off cap. It is guaranteed tamper-proof because the cap cannot be put back on once it has been removed, enabling the proprietary drug to be clearly distinguished from a possible counterfeited copy. In addition, this device avoids the need to have an extra aseptic area outside the lyophilizer, thus making savings on production.
The cap is made of plastic that can be sterilized by autoclaving with a maintained temperature of 121°C, yet is resistant to a temperature of -70°C required for freeze-drying. Two models will be available: .8 in. (20 mm) and .5 in. (13 mm).
BIOCORP won the New Innovative Technologies Award this year at the PDA Annual Meeting for its Lyoseal aseptic cap. It will be exhibiting next year at the PHARMAPACK trade show in Paris from Jan. 24 to 25 and at the PDA Annual Meeting in Las Vegas from March 19 to 23.
For more information, please contact :
BIOCORP
Alain Fontaine
Director Business Development
Biopole Clermont Limagne
63360 Gerzat, France
Tel: +33 (0)4 73 33 41 04
Fax: +33 (0)4 73 33 41 05
Mobile: +33 (0)6 76 06 14 19
E-mail: afontaine@biocorp.fr
Web: www.biocorp.fr
or
FRENCH TECHNOLOGY PRESS OFFICE
205 North Michigan Avenue, Suite 3740
Chicago, IL 60601
Fax: (312) 327-5261
E-mail: contact.ftpo@ubifrance.fr
